Good morning :)
Nureca Ltd

Nureca Ltd

NURECA Share Price

NSE
₹333.902.51% (-8.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹323 cr, stock is ranked 2,339

Stock is 4.02x as volatile as Nifty

NURECA Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹323 cr, stock is ranked 2,339

Stock is 4.02x as volatile as Nifty

NURECA Performance & Key Metrics

NURECA Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
75.131.79—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
45.855.740.50%

NURECA Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

NURECA Company Profile

Nureca Ltd is engaged in the marketing of home healthcare & wellness products

NURECA Similar Stocks (Peers)

Compare with peers Compare with peers 

NURECA Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.71
37.71
1Y Return
7.74%
7.74%
Buy Reco %
93.33
93.33
PE Ratio
83.90
83.90
1Y Return
33.34%
33.34%
Buy Reco %
81.48
81.48
PE Ratio
22.95
22.95
1Y Return
16.71%
16.71%
Buy Reco %
57.69
57.69
LAURUSLABS
PE Ratio
124.62
124.62
1Y Return
137.76%
137.76%
Buy Reco %
58.33
58.33
PE Ratio
27.91
27.91
1Y Return
12.30%
12.30%
Buy Reco %
62.86
62.86
Compare with Peers

NURECA Forecast

NURECA Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

NURECA

NURECA

Income

Balance Sheet

Cash Flow

NURECA Income Statement

NURECA Income Statement

Loading...

Quartermar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026
Total Revenue15.7126.0634.3627.9433.7336.7540.0641.8336.4242.16
Operating & Other expensessubtract21.4022.6433.5530.4830.5434.7434.4736.3941.1936.92
Depreciation/Amortizationsubtract0.600.660.620.540.520.530.540.500.450.61
Interest & Other Itemssubtract0.180.150.270.180.620.250.460.280.300.20
Taxes & Other Itemssubtract-2.320.960.41-0.45-0.410.420.970.930.591.37
EPS-4.151.66-0.48-2.802.470.813.633.91-6.453.21

NURECA Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual report

PDF
FY 2025FY 2025

Annual Report Unavailable

FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
 

NURECA Stock Peers

NURECA Past Performance & Peer Comparison

NURECA Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Nureca Ltd156.061.79—
Sun Pharmaceutical Industries Ltd37.715.160.89%
Torrent Pharmaceuticals Ltd83.9010.320.71%
Zydus Lifesciences Ltd22.953.910.09%

NURECA Stock Price Comparison

Compare NURECA with any stock or ETF
Compare NURECA with any stock or ETF
NURECA
Loading...

NURECA Holdings

NURECA Shareholdings

NURECA Promoter Holdings Trend

NURECA Promoter Holdings Trend

Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 3.12%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

NURECA Institutional Holdings Trend

NURECA Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

NURECA Shareholding Pattern

NURECA Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding68.09%0.00%0.24%0.11%31.57%

Dec 2025

Jan 2026

Mar 2026

Jun 2026

NURECA Shareholding History

NURECA Shareholding History

JunSepDec '25JanMarJun0.07%0.07%0.08%0.08%0.28%0.11%

NURECA Insider Trades & Bulk Stock Deals

NURECA Insider Trades & Bulk Stock Deals

Loading...

smallcases containing NURECA stock

smallcases containing NURECA stock

Looks like this stock is not in any smallcase yet.

NURECA Events

NURECA Events

NURECA Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

NURECA Dividend Trend

No dividend trend available

NURECA Upcoming Dividends

NURECA Upcoming Dividends

No upcoming dividends are available

NURECA Past Dividends

NURECA Past Dividends

Cash Dividend

Ex DateEx DateFeb 24, 2022

Interim
Interim | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Feb 24, 2022

Cash Dividend

Ex DateEx DateSep 21, 2021

Final
Final | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Sep 21, 2021

NURECA Stock News & Opinions

NURECA Stock News & Opinions

Corporate
Corporate
Nureca Limited closes trading window for insiders ahead of Q2/H1 2026 results

Nureca Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in the company's equity shares will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the second quarter and half-year ending September 30, 2026, prohibiting trading for designated persons and their immediate relatives.

1 week agoCapital Market - Live
Earnings
Earnings
Nureca consolidated net profit rises 279.01% in the June 2026 quarter

Net profit of Nureca rose 279.01% to Rs 3.07 crore in the quarter ended June 2026 as against Rs 0.81 crore during the previous quarter ended June 2025. Sales rose 18.02% to Rs 40.34 crore in the quarter ended June 2026 as against Rs 34.18 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales40.3434.18 18 OPM %8.48-1.64 - PBDT5.041.76 186 PBT4.431.23 260 NP3.070.81 279 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Corporate
Nureca announces board meeting date

Nureca will hold a meeting of the Board of Directors of the Company on 21 July 2026.

2 months agoCapital Market - Live
Spotlight
Spotlight
Nureca Ltd leads gainers in 'B' group

Hinduja Global Solutions Ltd, Wanbury Ltd, Fino Payments Bank Ltd and Orient Technologies Ltd are among the other gainers in the BSE's 'B' group today, 14 July 2026.Nureca Ltd surged 13.94% to Rs 280.3 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 21770 shares were traded on the counter so far as against the average daily volumes of 1218 shares in the past one month. Hinduja Global Solutions Ltd soared 12.99% to Rs 471.05. The stock was the second biggest gainer in 'B' group. On the BSE, 28493 shares were traded on the counter so far as against the average daily volumes of 10936 shares in the past one month. Wanbury Ltd spiked 12.62% to Rs 338.7. The stock was the third biggest gainer in 'B' group. On the BSE, 2.14 lakh shares were traded on the counter so far as against the average daily volumes of 12946 shares in the past one month. Fino Payments Bank Ltd jumped 11.61% to Rs 179.7. The stock was the fourth biggest gainer in 'B' group. On the BSE, 19.54 lakh shares were traded on the counter so far as against the average daily volumes of 98421 shares in the past one month. Orient Technologies Ltd advanced 11.54% to Rs 288.95. The stock was the fifth biggest gainer in 'B' group. On the BSE, 2.63 lakh shares were traded on the counter so far as against the average daily volumes of 18896 shares in the past one month. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Corporate
Nureca schedules AGM

Nureca announced that the 10th Annual General Meeting(AGM) of the company will be held on 28 July 2026.

3 months agoCapital Market - Live
Earnings
Earnings
Nureca reports consolidated net loss of Rs 6.09 crore in the March 2026 quarter

Net loss of Nureca reported to Rs 6.09 crore in the quarter ended March 2026 as against net profit of Rs 2.47 crore during the previous quarter ended March 2025. Sales rose 11.56% to Rs 35.41 crore in the quarter ended March 2026 as against Rs 31.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 144.71% to Rs 2.08 crore in the year ended March 2026 as against Rs 0.85 crore during the previous year ended March 2025. Sales rose 34.01% to Rs 146.96 crore in the year ended March 2026 as against Rs 109.66 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales35.4131.74 12 146.96109.66 34 OPM %-16.323.78 -0.12-6.88 - PBDT-5.062.57 PL 7.003.68 90 PBT-5.512.05 PL 4.981.34 272 NP-6.092.47 PL 2.080.85 145 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Corporate
Nureca to table results

Nureca will hold a meeting of the Board of Directors of the Company on 29 May 2026.

4 months agoCapital Market - Live
Spotlight
Spotlight
Nureca jumps on strong Q3 turnaround

Net profit stood at Rs 3.73 crore in Q3 FY26, compared with a loss of Rs 2.80 crore in Q3 FY25. On a sequential basis, PAT rose 2.8% from Rs 3.63 crore in Q2 FY26. Revenue from operations jumped 49.8% YoY to Rs 39.64 crore in Q3 FY26 from Rs 26.46 crore a year ago. Sequentially, revenue increased 5.0% from Rs 37.74 crore in Q2 FY26. Profit before tax stood at Rs 4.66 crore in Q3 FY26, compared with a loss of Rs 3.25 crore in the year-ago quarter, and was broadly flat sequentially versus Rs 4.60 crore in Q2 FY26. Total expenditure rose 19.4% YoY to Rs 36.39 crore during the quarter. Employee expenses increased 12.5% YoY to Rs 4.32 crore, while raw material costs surged 158.50% to Rs 10.34 crore from Rs 4.0 crore last year. Interest expense rose 55.56% YoY to Rs 0.28 crore from Rs 0.18 crore, while depreciation eased 7.4% YoY to Rs 0.50 crore. The management stated that the financial performance was primarily driven by enhanced operational efficiencies, improved sourcing strategies, and strengthened manufacturing capabilities. Focused cost optimization, tighter supply chain controls, and productivity improvements enabled better margins, while scalable manufacturing capabilities supported sustainable growth and consistent execution. Nureca continues to operate a digital-first, asset-light model, with over 90% of revenues generated through online channels. The company remains debt-free and maintains a healthy liquidity position. Nureca is a digital healthcare company focused on home healthcare and wellness products. Powered by Capital Market - Live

8 months agoCapital Market - Live
Earnings
Earnings
Nureca reports consolidated net profit of Rs 3.73 crore in the December 2025 quarter

Net profit of Nureca reported to Rs 3.73 crore in the quarter ended December 2025 as against net loss of Rs 2.80 crore during the previous quarter ended December 2024. Sales rose 49.81% to Rs 39.64 crore in the quarter ended December 2025 as against Rs 26.46 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales39.6426.46 50 OPM %8.20-15.19 - PBDT5.16-2.71 LP PBT4.66-3.25 LP NP3.73-2.80 LP Powered by Capital Market - Live

8 months agoCapital Market - Live
Corporate
Corporate
Nureca to table results

Nureca will hold a meeting of the Board of Directors of the Company on 17 January 2026.Powered by Capital Market - Live

8 months agoCapital Market - Live

Frequently asked questions

  1. The share price of NURECA as on 7th October 2026 is ₹333.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Nureca Ltd (NURECA) share are
    • Past 1 week: -5.94%
    • Past 1 month: 3.47%
    • Past 3 months: 46.76%
    • Past 6 months: 39.96%
    • Past 1 year: 42.03%
    • Past 3 years: -11.08%
    • Past 5 years: -83.18%

  3. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nureca Ltd (NURECA) is ₹323.04 Cr as of 7th October 2026.

  4. The 52-week high of Nureca Ltd (NURECA) is ₹376 and the 52-week low is ₹204.

  5. The P/E (price-to-earnings) ratio of Nureca Ltd (NURECA) is 156.06. The P/B (price-to-book) ratio is 1.79.

  6. Nureca Ltd (NURECA) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  7. You can directly buy Nureca Ltd (NURECA) shares on Tickertape. Simply sign up, connect your demat account and place your order.